AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma
Shots:
- The companies initiate P-III SAMETA study to evaluate the efficacy and safety of Hutchmeds savolitinib (MET tyrosine kinase inhibitor) + AstraZenecas Imfinzi (PD-L1 inhibitor) in treatment-naïve patients with MET-driven advanced PRCC. The first patient was dosed on Oct 28, 2021
- The 1EPs of the study is m-PFS & other EPs include m-OS, ORR, DoR, 6 & 12mos. DCR, time to second progression (PFS2), safety, PK, and QoL
- In 2011, the companies collaborated to jointly develop & commercialize savolitinib where Hutchmed will lead marketing authorization, manufacturing & supply of the therapy in China & AstraZeneca is responsible for the commercialization globally
Ref: Globenewswire | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com